Henry Ford Health

Henry Ford Health Scholarly Commons
Infectious Diseases Articles

Infectious Diseases

2-2-2021

Impact of pre-transplant carbapenem-resistant Enterobacterales
colonization and/or infection on solid organ transplant outcomes
Sarah Taimur
Stephanie M. Pouch
Nicole Zubizarreta
Madhu Mazumdar
Meenakshi Rana

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
infectiousdiseases_articles

Recommended Citation
Taimur S, Pouch SM, Zubizarreta N, Mazumdar M, Rana M, Patel G, Freire MP, Pellett Madan R, Kwak EJ,
Blumberg E, Satlin MJ, Pisney L, Clemente WT, Zervos MJ, La Hoz RM, and Huprikar S. Impact of pretransplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant
outcomes. Clin Transplant 2021.

This Article is brought to you for free and open access by the Infectious Diseases at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Infectious Diseases Articles by an authorized administrator of
Henry Ford Health Scholarly Commons.

Authors
Sarah Taimur, Stephanie M. Pouch, Nicole Zubizarreta, Madhu Mazumdar, Meenakshi Rana, Gopi Patel,
Maristela Pinnheiro Freire, Rebecca Pellett Madan, Eun Jeong Kwak, Emily Blumberg, Michael J. Satlin,
Larissa Pisney, Wanessa Trindade Clemente, Marcus J. Zervos, Ricardo M. La Hoz, and Shirish Huprikar

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
infectiousdiseases_articles/145

Received: 12 January 2021

|

Revised: 19 January 2021

|

Accepted: 22 January 2021

DOI: 10.1111/ctr.14239

ORIGINAL ARTICLE
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Abstract
The impact of pre-transplant (SOT) carbapenem-resistant Enterobacterales (CRE) colonization or infection on post-SOT outcomes is unclear. We conducted a multi-center,
international, cohort study of SOT recipients, with microbiologically diagnosed CRE
colonization and/or infection pre-SOT. Sixty adult SOT recipients were included (liver
n = 30, hearts n = 17). Klebsiella pneumoniae (n = 47, 78%) was the most common pre-
SOT CRE species. Median time from CRE detection to SOT was 2.32 months (IQR
0.33–10.13). Post-SOT CRE infection occurred in 40% (n = 24/60), at a median of
9 days (IQR 7–17), and most commonly due to K pneumoniae (n = 20/24, 83%). Of
those infected, 62% had a surgical site infection, and 46% had bloodstream infection.
Patients with post-SOT CRE infection more commonly had a liver transplant (16, 67%
vs. 14, 39%; p =.0350) or pre-SOT CRE BSI (11, 46% vs. 7, 19%; p =.03). One-year
post-SOT survival was 77%, and those with post-SOT CRE infection had a 50% less
chance of survival vs. uninfected (0.86, 95% CI, 0.76–0.97 vs. 0.34, 95% CI 0.08–1.0,
p =.0204). Pre-SOT CRE infection or colonization is not an absolute contraindication
to SOT and is more common among abdominal SOT recipients, those with pre-SOT
CRE BSI, and those with early post-SOT medical and surgical complications.
KEYWORDS

carbapenem-resistant enterobacterales, multidrug-resistant organisms, solid organ
transplantation
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BAC KG RO U N D

or total artificial heart and device-related infection as applicable (heart
transplant recipients only); cystic fibrosis (lung transplant recipients

Infections due to carbapenem-resistant Enterobacterales (CRE) are

only); age at the time of SOT; pre-SOT CRE isolated with identified

an evolving global public health threat and are associated with high

mechanism of resistance as available; source of pre-SOT CRE; organ

mortality and healthcare costs.1,2 Therapeutic challenges asso-

transplanted; alteration of standard peri-operative prophylaxis based

ciated with CRE infections are immense due to the ability of car-

upon CRE history with alternate agent(s) used as applicable; induc-

bapenemases to hydrolyze almost all beta-lactams and frequent

tion and maintenance immunosuppressive regimens; post-SOT sur-

concomitant resistance to other classes of antibiotics such as ami-

gical complications (bleeding, anastomotic leak, thrombosis, and

noglycosides and fluoroquinolones.3,4 Emergence of resistance to

re-
operation); post-
SOT medical complications (renal replacement

CRE-active agents such as polymixins, tigecycline, and ceftazidime-

therapy, tracheobronchitis in lung transplant recipients only, early al-

avibactam has also been reported, further limiting therapeutic op-

lograft rejection [rejection within 30 days of SOT], and delayed graft

tions for patients with CRE infections. 5-11

function); development of post-SOT CRE infection with time to infec-

Solid organ transplantation (SOT) is an independent risk factor
3

tion, type of infection, and CRE organism isolated as applicable.

for CRE infection. The rate of CRE infections in the SOT population

Source of pre-SOT CRE detection was classified based on type of

varies by region and organ transplanted. Incidence rates of 3%–10%

specimen as surveillance cultures representing colonization, or clini-

have been reported among SOT recipients in CRE-endemic areas,1,12

cal cultures representing colonization or infection.

and CRE infections have been associated with mortality rates between 30% and 50%.

2,12

CRE colonization has been associated with post-SOT CRE in-

CRE infection (pre-and post-SOT) was defined as the isolation of
CRE in a clinical specimen in the presence of clinical signs and symptoms of infection. CRE colonization was defined as isolation of CRE in a

fection13-16; however, most data are limited to single center studies

surveillance specimen, or in a clinical specimen in the absence of clinical

and pertain to abdominal transplantation only. While CRE coloniza-

signs and symptoms of infection. Pre-and post-SOT CRE species were

tion or previous infection is not an established contraindication to

considered concordant whether the same species of CRE was detected

transplantation,17,18 impact on post-SOT outcomes is not well un-

microbiologically. Typing of bacterial strains was not performed.

derstood, and there is little guidance on peri-operative antimicrobial
management in this setting. Therefore, we conducted this study to
evaluate the clinical outcomes of patients who underwent SOT with

2.3 | Microbiologic testing

prior CRE infection and/or asymptomatic colonization.
The clinical microbiology laboratories at each participating site per-

2
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M E TH O D S

2.1 | Settings and study population

formed bacterial identification and antimicrobial susceptibility testing of bacterial isolates and applied the 2013 Clinical and Laboratory
Standards Institute (CLSI) interpretive breakpoints for diagnosis of
carbapenem resistance.19 Additional testing for the presence of carbapenemases was not required for inclusion in the study but was per-

This multi-center, retrospective, and international cohort study evalu-

formed at some sites using either traditional biochemical (Modified

ated adults (≥18 years of age) who underwent SOT from January 1, 2007

Hodge testing) or molecular methodology (polymerase chain reaction),

to July 31, 2013 and who had confirmed pre-SOT CRE colonization and/

depending on the laboratory protocol of participating center.20

or infection at any time prior to SOT. We recruited study sites via email
notification using the American Society of Transplant Infectious Diseases
Community of Practice (AST ID COP) hub. Each participating site ob-

2.4 | Statistical analysis

tained Institutional Review Board approval. Sites were asked to identify
patients without specifying the procedure to do so. The Icahn School

Descriptive statistics were used to report key variables for the full

of Medicine at Mount Sinai in New York City served as the host study

cohort and for those with and without post-
SOT CRE infection.

site, and each participating site submitted de-identified demographic,

Continuous variables were expressed as medians and interquartile

clinical, and microbiologic data to a centralized database at Mount Sinai

ranges (IQRs) and were compared using the Mann-Whitney U test.

for analysis. Each site co-investigator reviewed relevant patient medical

Categorical variables were expressed as frequencies and percentages

records through date of patient death or last follow-up.

and compared using the chi-square or Fisher's exact test as appropriate. As a post hoc analysis, we looked to see if there is a difference in

2.2 | Clinical data and definitions

outcomes for patients who had a SOT within 1 year of CRE diagnosis vs
patients who had a SOT >1 year after CRE diagnosis. Due to the time-
dependent nature of the patient developing a post-transplant CRE in-

The following variables were collected for each patient: gender; pre-

fection, overall survival was depicted using the method by Simon and

SOT renal replacement therapy (kidney transplant recipients only), in-

Makuch.21 Comparisons of time to event distributions among those

dication for liver transplantation; presence of ventricular assist device

who developed a post-transplant infection were evaluated using the

|
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time-dependent Cox regression model. A two-tailed p-value <.05 was

patients with post-SOT CRE K pneumoniae infection, 19 had pre-

considered statistically significant. All analyses were performed using

SOT evidence of the same bacteria; detected in the bloodstream

SAS v.9.4 statistical software (SAS Institute).

in 9 patients, and in other sites in 10 patients (Table 2). For the
one remaining patient with post-SOT CRE K pneumoniae infection,

3
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Klebsiella oxytoca was diagnosed on culture of LVAD exit site pre-
SOT. Among the three patients who had post-SOT CRE Enterobacter
cloacae infection, the same was detected pre-SOT in two patients

The study cohort consisted of 60 SOT recipients with CRE coloni-

(1 BSI and rectal colonization, 1 respiratory and rectal colonization).

zation and/or infection diagnosed at a median of 2.3 months (IQR

The remaining one patient with post-SOT E cloacae infection had K

0.33–10.13) before transplantation. The most common type of organ

pneumoniae rectal colonization and BSI diagnosed pre-SOT. There

transplant was liver (LT, n = 30; 50%) followed by heart (HT, n = 17;

was only one patient with post-SOT CRE Serratia marcescens infec-

28%) and kidney (KT, n = 7; 12%). A total of 30 patients received in-

tion, who had rectal colonization due to the same detected pre-SOT.

duction immunosuppression; 19 (63%) received IL-2 receptor antago-

We investigated potential association of key pre-and post-SOT

nists; 10 (33%) received anti-thymocyte globulin; and 1 (3%) received

variables with post-SOT CRE infection. The results of univariable

alemtuzumab. Organ types that received induction immunosuppres-

analysis are outlined in Table 1. Due to small outcome size, a multi-

sion included LT (n = 11), HT (n = 9), KT (n = 7) lung transplant (n = 2),

variable analysis was not performed. The distribution of organ types

and intestine (ITX, n = 1). Five patients in the cohort (8%) were re-

between those with post-SOT CRE infection and those without was

transplant recipients (4 LT, 1 LT/KT; Table 1).

significantly different, and those with post-SOT CRE infection were
more likely to have undergone LT (16, 67% vs. 14, 39%; p =.0350).

3.1 | Pre-transplant CRE infection and colonization

Those with post-SOT CRE infection were also more likely to have
had pre-SOT CRE BSI than those without (11/24, 46% vs. 7/36,
19%, p =.03). Among those who developed post-SOT CRE infection,

Pre-SOT CRE was isolated in 34 clinical and 26 surveillance speci-

the median time from most recent pre-SOT CRE (detected closest to

mens (Table 1). Among the clinical specimens with CRE, definitive

transplant) and transplant surgery, was significantly shorter versus

distinction between colonization and infection could not be made

those who did not develop infection post-SOT (0.9, 0.1–3.1 vs. 4.2,

for 16/60 isolates (4 from the respiratory tract, 12 from the urine).

0.5–13.6 months, p =.0168). When looked at in the sub-group of pa-

Thirty percent of the total cohort (n = 18) was diagnosed with pre-

tients with pre-SOT BSI (n = 18/60), this difference was smaller but

SOT CRE bloodstream infection at a median of 1.84 (0–29) months

remained statistically significant [1.00, 0–23 vs. 11.8, 0.4–29 months,

prior to SOT. The most common pre-SOT CRE species was Klebsiella

p =.05). Peri-operative prophylaxis targeted to pre-SOT CRE species

pneumoniae (n = 47, 78%), followed by Enterobacter cloacae (n = 4,

was more common among patients with post-SOT CRE infection than

7%). The mechanism of CRE resistance was known for 29 (48%) iso-

those without (13/24, 54% vs. 8/36, 22%, p =.0145). Of the 21 total

lates, of which 21 were identified by modified Hodge testing and 8

patients who received targeted prophylaxis, 10 (48%) had a history of

by polymerase chain reaction (7 were positive for Klebsiella pneumo-

pre-SOT CRE bacteremia, and 11 (52%) patients had CRE detected in

niae carbapenemases [KPC] and 1 isolate was positive for New-Delhi

urine (n = 5), rectal surveillance swab (n = 4) and LVAD exit site (n = 2).

metallo-beta-lactamase [NDM-1]).

We also conducted a univariate analysis to see if there was a difference in patient characteristics and outcomes, when compared by

3.2 | Post-transplant CRE infection

time of CRE detection in relation with time of SOT. Using the time of
CRE detection closest to SOT, there was no significance difference
in patient characteristics except type of organ transplant (LT n = 28

Post-SOT infection occurred in 40% (n = 24/60) of the total cohort at a

vs. 2, KT 2 vs. 5, LT/KT 2 vs. 1, ITX 0 vs. 1, Lung 2 vs 0, HT 13 vs. 4,

median of 9 (7–17) days after transplant and most commonly involved

p =.0014), among those who had pre-SOT CRE detected ≤12 months

the surgical site (SSI) (n = 15/24, 62%), urinary tract (6/24, 25%), and

and >12 months from time of SOT. Similarly, there was no significant

lungs (n = 3/24, 12.5%). Majority of infections occurred in LT recipients

difference between the groups in post-SOT outcomes of CRE infec-

(n = 16/24; 9 SSI, 2 pneumonia, 5 urinary tract infections), followed by

tion, re-transplantation, mortality within transplant hospitalization,

HT (n = 4/24; 3 SSI, 1 urinary tract infection), LT/KT (n = 2/24; both

and 1-year post-SOT mortality (data not shown).

SSI), LTX (n = 1/24; pneumonia) and ITX recipients (n = 1/24; 1 SSI).
Secondary bloodstream infection (BSI) was seen in 46% of those infected (n = 11/24), and the majority of these were associated with surgical site infection [9/11, 82%]. Fourteen of 24 patients were in the ICU

3.3 | Post-transplant medical and surgical
complication

at the time of post-SOT infection diagnosis with a median ICU stay of
11 days (2–32), and 10 died within the transplant hospitalization.

Patients with post-transplant CRE infection more commonly had

Species concordance between pre-  and post-SOT CRE species

complications including post-
transplant surgery (14/24, 58% vs.

was observed most commonly for Klebsiella pneumoniae. Of the 20

3/36, 8%, p <.0001) and medical complications including renal

4 of 7
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TA B L E 1 Pre- and post-transplant characteristics by post-transplant infection outcome
Patient characteristic

Post-SOT CRE infection
(n = 24)

No post-SOT CRE infection
(n = 36)

p-value

Median age at transplant, years (IQR)

55 (48–61)

52 (45–61)

.6129

Male gender, n (%)

15 (62.5)

25 (69.4)

.5762

Liver

16 (66.7)

14 (38.9)

.0143

Heart

4 (16.7)

13 (36.1)

Kidney

0 (0.0)

7 (19.4)

Organ transplant type, n (%)

Liver-kidney

2 (8.3)

1 (2.8)

Intestine

1 (4.2)

0 (0.0)

Lungs

1 (4.2)

1 (2.8)

3 (12.5)

2 (5.56)

.3803

10 (41.67)

20 (55.56)

.2918

IL-2 Receptor antagonist

7 (70.0)

12 (60.0)

Anti-thymocyte Globulin

3 (30.0)

7 (35.0)

Alemtuzumab

0 (0.0)

1 (5.0)

20 (83.3)

27 (75.0)

1 (4.2)

1 (2.8)

Re-transplantation, n (%)
Induction immunosuppression, n (%)

Pre-SOT CRE species, n (%)
K pneumoniae
K oxytoca
C freundii

0 (0.0)

1 (2.8)

E cloacae

2 (8.3)

2 (5.6)

.6340

E coli

0 (0.0)

4 (11.1)

S marcescens

1 (4.2)

1 (2.8)

11 (45.8)

7 (19.4)

.0289

Rectal

4 (16.7)

13 (36.1)

.0524

Pre-transplant CRE bacteremia
Site of most recent pre-SOT CRE identification
Surveillance specimens
Respiratory

0 (0.0)

3 (8.3)

Urine

2 (8.3)

6 (16.7)

Wound

0 (0.0)

1 (2.8)

Clinical specimens
Blood

9 (37.5)

4 (11.1)

Surgical site

1 (4.2)

2 (5.6)

Respiratory

4 (16.7)

1 (2.8)

Urine Culture

4 (16.7)

6 (16.7)

13 (54.2)

8 (22.2)

.0145
<.0001

Receipt of CRE-active peri-operative prophylaxis, n (%)
Post-SOT surgical complications prior to CRE infection, n (%)
Anastomotic leak

2 (8.3)

0 (0.0)

Bleeding

1 (4.2)

3 (8.3)

10 (41.7)

0 (0.0)

Other

Reoperation

1 (4.2)

0 (0.0)

None

10 (41.7)

33 (91.7)

Post-SOT medical complications prior to CRE infection, n (%)
Renal replacement therapy

8 (33.3)

3 (8.3)

Early rejection

2 (8.3)

1 (2.8)

Other

1 (4.2)

1 (2.8)

None

13 (54.2)

31 (86.1)

.0186

(Continues)
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TABLE 1 (Continued)
Patient characteristic
Median time from most recent pre-transplant CRE detection to
transplant, months (IQR)

Post-SOT CRE infection
(n = 24)

No post-SOT CRE infection
(n = 36)

p-value

0.9 (0.1–3.1)

4.2 (0.5–13.6)

.0168

Mortality during SOT hospitalization, n (%)

6 (25.0)

3 (8.3)

.0859b

1-year post-SOT mortality, n (%)

8 (33.3)

6 (16.7)

.1286b

Abbreviation: IQR, Interquartile range.
a

Mann-Whitney U test for continuous variables and chi-square/Fisher’s exact test for categorical variables

b

Time to event outcomes compared using the log-rank test.

Bold p-values are explained in paragraph form where the table is referenced

replacement therapy prior to onset of post-
SOT CRE infection

4

|

DISCUSSION

(11/24, 46% vs. 5/36, 14%, p =.0186). One-year post-SOT survival
for the entire cohort was 77%, and those with post-SOT CRE infec-

This is the first international, multi-center investigation of out-

tion had a 50% less chance of survival than those without (0.86;

comes in SOT recipients with pre-SOT CRE colonization and/or

95% CI, 0.76–0.97 vs. 0.34; 95% CI 0.08–1.00; log rank p =.0204;

infection. Overall one-year survival for the cohort was 77%. This

Figure 1).

is an important finding as the significance of CRE colonization or

TA B L E 2 Pre-transplant microbiology of patients with post-transplant infection (n = 24)
Pre-SOT CRE
species

Site of Pre-SOT CRE

Targeted surgical
prophylaxis

SOT type

Post-SOT CRE
species.

Post-SOT
infection site

Secondary
BSI

K pneumoniae

Bld, Ur, rectum, resp

Yes

LT

K pneumoniae

Pna

No

K pneumoniae

Rectum

No

LT, KT

K pneumoniae

SSI

No

K pneumoniae

Bld, rectum

Yes

LT

K pneumoniae

SSI

Yes

K pneumoniae

Bld

Yes

LT

K pneumoniae

SSI

Yes

K pneumoniae

Resp, Ur

No

LT

K pneumoniae

Pna

Yes

K pneumoniae

Ur

Yes

LT

K pneumoniae

UTI

No

K pneumoniae

Ur

No

LT

K pneumoniae

UTI

No

S marcescens

Rectum

No

LT

S marcescens

SSI

Yes

K pneumoniae

Bld, rectum

No

LT

K pneumoniae

SSI

Yes

K pneumoniae

Bld

No

LT

K pneumoniae

SSI

Yes

K pneumoniae

Resp

No

LT

K pneumoniae

SSI

No

K pneumoniae

Bld

No

LT

K pneumoniae

UTI

No

K pneumoniae

Resp

Yes

HT

K pneumoniae

SSI

Yes

K pneumoniae

Ur

No

LT

K pneumoniae

UTI

No

K oxytoca

DLI

Yes

HT

K pneumoniae

UTI

Yes

K pneumoniae

Ur

Yes

LTX

K pneumoniae

Pna

No

K pneumoniae

Ur

Yes

LT, KT

K pneumoniae

SSI

No

K pneumoniae

Bld, rectum

Yes

ITX

E cloacae

SSI

Yes

E cloacae

Resp, rectum

Yes

HT

E cloacae

SSI

Yes

E cloacae

Bld, rectum

Yes

HT

E cloacae

SSI

No

K pneumoniae

Ur

Yes

LT

K pneumoniae

SSI

No

K pneumoniae

Bld, Ur

Yes

LT

K pneumoniae

SSI

Yes

K pneumoniae

Bld

No

LT

K pneumoniae

UTI

No

K pneumoniae

Bld, rectum

No

LT

K pneumoniae

SSI

No

Abbreviations: Bld, blood; BSI, bloodstream infection; DLI, LVAD driveline exit-site; E cloacae, Enterobacter cloacae; K pneumoniae/oxytoca, Klebsiella
pneumoniae/oxytoca; Pna, pneumonia; Rectum, rectal surveillance specimen; Resp, respiratory; S marcescens, Serratia marcescens; SSI, surgical site
infection; Ur, urine; UTI, urinary tract infection.

6 of 7

|

TAIMUR et al.

of pre-SOT CRE detection closest to time of SOT, we were unable to detect any difference in post-SOT infection and mortality.
Nonetheless, we feel this an important finding that warrants further investigation in future studies.
Peri-SOT prophylaxis targeted to CRE was given to 35% of
patients in our cohort; however, details of the regimen used was
not available for most. Of the cases where this information was
available, targeted prophylaxis consisted primarily of a combination of 2 to 3 agents, most commonly carbapenems, polymixins,
and tigecycline. Data on antimicrobial dosing and duration of peri-
operative prophylaxis were not collected. Interestingly, we found
that patients who received targeted CRE prophylaxis more commonly developed post-transplant CRE infection than those who
did not. Multiple factors likely account for this finding. Nearly 48%
of patients who received targeted prophylaxis had pre-t ransplant
CRE BSI (10/21) and were at greater risk of post-SOT infection
despite targeted prophylaxis. Furthermore, the adequacy of targeted prophylaxis for this cohort is unknown, and type of antibiF I G U R E 1 Time dependent one-year post-SOT survival
estimate—post-SOT CRE infection vs. none: 0.338 (95% CI 0.080,
1.000) vs. 0.857 (95% CI 0.755–0.973), p =.0204

otic regimen may have contributed to the risk of infection. It is also
important to note that novel and potentially more effective agents
for treatment of CRE such as ceftazidime-avibactam23 were not
available in the timeframe of this study. Based on our data it is
therefore unclear, if peri-operative prophylaxis targeted to pre-

infection prior to SOT was unknown prior to this study. As the

SOT CRE species is indicated. However, the presence of concor-

global multi-drug resistant organism (MDRO) epidemic grows, the

dance between the most common pre- and post-CRE SOT species,

CDC

19

and WHO

22

recommend that all healthcare institutions de-

speaks of the high risk of post-SOT infection due to pre-SOT col-

velop a multi-m odal approach including surveillance to prevent

onizing and infecting pathogens, highlighting the importance of

CRE infections. Many transplant institutions are already conduct-

targeted empiric antibiotic therapy in patients who develop signs

ing screening of SOT candidates for MDRO colonization to imple-

and symptoms of infection post-SOT. This study further reiterates

ment targeted infection prevention measures, and in future, these

the high risk of CRE infection among abdominal transplant recip-

practices may become even more widespread if validated by stud-

ients, those with post-t ransplant surgical complications and post-

ies. This study shows that pre-SOT CRE colonization or infection

transplant renal failure requiring renal replacement therapy.

is not an absolute contraindication to SOT and is associated with

This study has several limitations including a retrospective de-

favorable one-year post-SOT survival in nearly 80% of patients.

sign, and the lack of a multivariable analysis due the small number

Our findings also shed some light on the risk of post-SOT infection

of patients with post-transplant infection. An adjusted analysis to

conferred by different sites of pre-SOT CRE detection, although

ascertain independent infection predictors should be pursued in

we were not able to confirm these findings in an adjusted analysis.

the future to confirm the findings of this study. Due to lack of clin-

We found that pre-SOT CRE BSI was significantly more common

ical information, we were not able to discern pre-SOT CRE infec-

among those who developed post-SOT CRE infection. There was

tion from colonization in 16 non-blood clinical specimens. While we

otherwise no difference in the percent of patients with post-SOT

were able to show the impact of pre-SOT CRE BSI, we are unable to

infection by site of pre-SOT CRE detection in this cohort. This find-

provide the same clarity on the post-SOT infection risk conferred by

ing is a step toward the much-n eeded clarity about this commonly

pre-SOT CRE colonization versus active infection in other sites. We

encountered issue, and informs us of the risk of post-transplant

must also acknowledge that the CLSI MIC breakpoints for CRE were

CRE infection in colonized and infected transplant candidates. We

updated since this study. However, the clinical significance of these

also found that in patients who developed post-SOT CRE infec-

breakpoint changes and the percent change in species susceptibility

tion, the time between the most recent pre-SOT CRE (any site)

does not appear to be universally significant. 24,25 Hence, we feel this

and transplantation was significantly shorter for those who than

change does not influence the relevance of these findings.

those did not develop infection following SOT, and this difference
while smaller, remained significant for patients with pre-SOT BSI
only. This finding suggests that detection of CRE infection or colo-

5
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nization closer to time of transplantation may carry greater risk of
post-SOT infection, than CRE detected more remotely pre-SOT.

In our retrospective cohort study, 77% of SOT recipients with pre-

However, in a separate analysis dividing the study cohort by time

CRE colonization or infection were alive one year after SOT, although

|
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post-SOT CRE infection was associated with reduced survival. Post-
transplant CRE infection occurred more commonly among abdominal
transplant recipients, those with pre-SOT CRE BSI, and those with

11.

post-transplant surgical complications and renal replacement therapy.
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